Three-Times-Weekly Administration of Teriparatide Improves Vertebral and Peripheral Bone Density, Microarchitecture, and Mechanical Properties Without Accelerating Bone Resorption in Ovariectomized Rats

Verfasser / Beitragende:
[Ryoko Takao-Kawabata, Yukihiro Isogai, Aya Takakura, Yukari Shimazu, Emika Sugimoto, Osamu Nakazono, Ichiro Ikegaki, Hiroshi Kuriyama, Shinya Tanaka, Hiromi Oda, Toshinori Ishizuya]
Ort, Verlag, Jahr:
2015
Enthalten in:
Calcified Tissue International, 97/2(2015-08-01), 156-168
Format:
Artikel (online)
ID: 60552095X
LEADER caa a22 4500
001 60552095X
003 CHVBK
005 20210128100737.0
007 cr unu---uuuuu
008 210128e20150801xx s 000 0 eng
024 7 0 |a 10.1007/s00223-015-9998-0  |2 doi 
035 |a (NATIONALLICENCE)springer-10.1007/s00223-015-9998-0 
245 0 0 |a Three-Times-Weekly Administration of Teriparatide Improves Vertebral and Peripheral Bone Density, Microarchitecture, and Mechanical Properties Without Accelerating Bone Resorption in Ovariectomized Rats  |h [Elektronische Daten]  |c [Ryoko Takao-Kawabata, Yukihiro Isogai, Aya Takakura, Yukari Shimazu, Emika Sugimoto, Osamu Nakazono, Ichiro Ikegaki, Hiroshi Kuriyama, Shinya Tanaka, Hiromi Oda, Toshinori Ishizuya] 
520 3 |a Daily and weekly administration of teriparatide (PTH1-34) reduces the risk of osteoporotic bone fractures. However, their effects on markers of bone formation and bone resorption differ. These results indicate that the dosing frequency of teriparatide may affect bone metabolism and bone structure, with different effects on bone strength. In the present study, to evaluate the dose-related effects of a low administration frequency of teriparatide on bone status, we investigated the effects of three-times-weekly administration of teriparatide (1.1, 5.6, or 28.2µg/kg) for 12months on bone parameters, including bone metabolism markers, bone mineral density (BMD), micro-computed tomography, and bone strength, using 6-month-old ovariectomized (OVX) rats. Three-times-weekly administration of teriparatide dose-dependently increased the BMD of the lumbar vertebra and femur in OVX rats, and increased serum osteocalcin (a marker of bone formation), but not type I collagen C-telopeptide (a marker of bone resorption). The trabecular number and thickness increased in the vertebrae and femur, as in prior reports of daily teriparatide administration in OVX rats. Cortical thickness increased only toward the endocortical side of the femur, unlike with daily administration. Bone strength of the vertebrae and proximal and shaft of the femur was correlated with the changes in BMD and bone structure. These results demonstrate the effects of low frequency, intermittent administration of teriparatide on the biomechanical, and microstructural properties of bone in OVX rats. 
540 |a The Author(s), 2015 
690 7 |a Teriparatide  |2 nationallicence 
690 7 |a Three-times-weekly  |2 nationallicence 
690 7 |a Bone metabolism  |2 nationallicence 
690 7 |a Mechanical strength  |2 nationallicence 
690 7 |a Micro-computed tomography  |2 nationallicence 
700 1 |a Takao-Kawabata  |D Ryoko  |u Laboratory for Pharmacology, Pharmaceuticals Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, Izunokuni, 410-2321, Shizuoka, Japan  |4 aut 
700 1 |a Isogai  |D Yukihiro  |u Laboratory for Pharmacology, Pharmaceuticals Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, Izunokuni, 410-2321, Shizuoka, Japan  |4 aut 
700 1 |a Takakura  |D Aya  |u Laboratory for Pharmacology, Pharmaceuticals Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, Izunokuni, 410-2321, Shizuoka, Japan  |4 aut 
700 1 |a Shimazu  |D Yukari  |u Laboratory for Pharmacology, Pharmaceuticals Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, Izunokuni, 410-2321, Shizuoka, Japan  |4 aut 
700 1 |a Sugimoto  |D Emika  |u Laboratory for Pharmacology, Pharmaceuticals Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, Izunokuni, 410-2321, Shizuoka, Japan  |4 aut 
700 1 |a Nakazono  |D Osamu  |u Laboratory for Pharmacology, Pharmaceuticals Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, Izunokuni, 410-2321, Shizuoka, Japan  |4 aut 
700 1 |a Ikegaki  |D Ichiro  |u Laboratory for Pharmacology, Pharmaceuticals Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, Izunokuni, 410-2321, Shizuoka, Japan  |4 aut 
700 1 |a Kuriyama  |D Hiroshi  |u Laboratory for Pharmacology, Pharmaceuticals Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, Izunokuni, 410-2321, Shizuoka, Japan  |4 aut 
700 1 |a Tanaka  |D Shinya  |u Department of Orthopaedic Surgery, Saitama Medical University, 38 Morohongo, Moroyama-cho, Iruma-gun, 350-0495, Saitama, Japan  |4 aut 
700 1 |a Oda  |D Hiromi  |u Department of Orthopaedic Surgery, Saitama Medical University, 38 Morohongo, Moroyama-cho, Iruma-gun, 350-0495, Saitama, Japan  |4 aut 
700 1 |a Ishizuya  |D Toshinori  |u Laboratory for Pharmacology, Pharmaceuticals Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, Izunokuni, 410-2321, Shizuoka, Japan  |4 aut 
773 0 |t Calcified Tissue International  |d Springer US; http://www.springer-ny.com  |g 97/2(2015-08-01), 156-168  |x 0171-967X  |q 97:2<156  |1 2015  |2 97  |o 223 
856 4 0 |u https://doi.org/10.1007/s00223-015-9998-0  |q text/html  |z Onlinezugriff via DOI 
898 |a BK010053  |b XK010053  |c XK010000 
900 7 |a Metadata rights reserved  |b Springer special CC-BY-NC licence  |2 nationallicence 
908 |D 1  |a research-article  |2 jats 
949 |B NATIONALLICENCE  |F NATIONALLICENCE  |b NL-springer 
950 |B NATIONALLICENCE  |P 856  |E 40  |u https://doi.org/10.1007/s00223-015-9998-0  |q text/html  |z Onlinezugriff via DOI 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Takao-Kawabata  |D Ryoko  |u Laboratory for Pharmacology, Pharmaceuticals Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, Izunokuni, 410-2321, Shizuoka, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Isogai  |D Yukihiro  |u Laboratory for Pharmacology, Pharmaceuticals Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, Izunokuni, 410-2321, Shizuoka, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Takakura  |D Aya  |u Laboratory for Pharmacology, Pharmaceuticals Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, Izunokuni, 410-2321, Shizuoka, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Shimazu  |D Yukari  |u Laboratory for Pharmacology, Pharmaceuticals Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, Izunokuni, 410-2321, Shizuoka, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Sugimoto  |D Emika  |u Laboratory for Pharmacology, Pharmaceuticals Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, Izunokuni, 410-2321, Shizuoka, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Nakazono  |D Osamu  |u Laboratory for Pharmacology, Pharmaceuticals Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, Izunokuni, 410-2321, Shizuoka, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Ikegaki  |D Ichiro  |u Laboratory for Pharmacology, Pharmaceuticals Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, Izunokuni, 410-2321, Shizuoka, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Kuriyama  |D Hiroshi  |u Laboratory for Pharmacology, Pharmaceuticals Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, Izunokuni, 410-2321, Shizuoka, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Tanaka  |D Shinya  |u Department of Orthopaedic Surgery, Saitama Medical University, 38 Morohongo, Moroyama-cho, Iruma-gun, 350-0495, Saitama, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Oda  |D Hiromi  |u Department of Orthopaedic Surgery, Saitama Medical University, 38 Morohongo, Moroyama-cho, Iruma-gun, 350-0495, Saitama, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Ishizuya  |D Toshinori  |u Laboratory for Pharmacology, Pharmaceuticals Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, Izunokuni, 410-2321, Shizuoka, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 773  |E 0-  |t Calcified Tissue International  |d Springer US; http://www.springer-ny.com  |g 97/2(2015-08-01), 156-168  |x 0171-967X  |q 97:2<156  |1 2015  |2 97  |o 223